The FDA's drug approvals database records a supplemental application on baricitinib, NDA 207924, held by Eli Lilly, dated 25 September 2026. That is the whole of what the entry states: the application number, the sponsor and the molecule.
A supplement is not a new approval and is not one kind of thing. It may cover a manufacturing or labelling change, a new formulation or strength, a paediatric study requirement, a safety-related label revision, or a new indication — and these have entirely different consequences for a prescriber. The record here does not distinguish between them, so nothing should be inferred about baricitinib's indications changing.
What this does warrant is a check rather than a change. Where you prescribe baricitinib, the current prescribing information is the document to read, not this entry; a label revision that matters will appear there. Baricitinib in India is available from several manufacturers and its Indian labelling is set by CDSCO, which has made no corresponding statement, so an American supplement does not alter what is licensed here.
- Do not read a supplemental application as a new indication — supplements cover manufacturing, labelling, formulation and safety changes too
- Check the current prescribing information rather than this entry if you prescribe baricitinib
- Indian labelling is set by CDSCO and is unaffected by an American supplemental application
- Continue existing baricitinib monitoring unchanged; nothing in this record indicates a safety finding
- Watch the label rather than the approvals database for the change that would actually affect prescribing
Why it matters
A database entry with no scope is routinely reported as an approval, and a supplement usually is not one.
Don't overread it
This is an administrative record of a supplemental application, not a safety finding and not a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free